OraSure Technologies, Inc. Healthcare | Medical Instruments & Supplies | USA OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV1/2, OraQuick HIV self-test, OraQuick HCV, OraQuick In-Home HIV test, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, OMNIgene GUT, OMNIgene SPUTUM, PrepIT MAX, OMNIgene VAGINAL, OMNIgene ORAL, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company offers oral fluid collection devices to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, pharmacogenomics, personalized medicine, microbiome and animal genetics, and academic research markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.
Stock has had a great run, but there is more potential too. Trades 800k shares/day, right at $1B market cap. Involved in Oragene, which is a product whereby you can do genetic testing from saliva, rather than blood. Much easier to collect a spit sample (hey it is what it is) or a mouthswab -- anyone can do this at home -- than it is to send a phlebotomist with a needle to draw blood.
Hmmmm interesting concept. Gonna add it to my watchlist and wait for a dip to decide if I want to pursue it! Thanks for bringing it up
Grabbed the Jan 17.5s @ .65 today This was just when it started to breakout. it was 15.50 at the time
This got beat down big time, but looks to have found a bottom. Revenues this year are lower than previous 2 years (hence the beatdown). But their Q2 report forecast $170M revenues this year, which means they think they can make $62M in Q4, and that would be a record. We'll have to see if they revise that forecast lower in next ER. But they're saying microbiome and HIV testing revenues can grow 10-20% next year. So this seems like a temporary bottom at least. If it rips, then take profits and see if you can get a pullback (possibly even down to current levels again).
